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The impact of micronized progesterone on breast cancer risk: a systematic
review
P. Stutea, L. Wildtb and J. Neulenc
aDepartment of Obstetrics and Gynecology, University of Bern, Bern, Switzerland; bDepartment of Gynecological Endocrinology and
Reproductive Medicine, Medical University of Innsbruck, Innsbruck, Austria; cClinic for Gynecological Endocrinology and Reproductive
Medicine, RWTH University of Aachen, Aachen, Germany
ABSTRACT
Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen
for endometrial protection. The debate on bioidentical hormones including micronized progesterone
has increased in recent years. Based on a systematic literature review on the impact of menopausal
hormone therapy (MHT) containing micronized progesterone on the mammary gland, an international
expert panel’s recommendations are as follows: (1) estrogens combined with oral (approved) or vaginal
(off-label use) micronized progesterone do not increase breast cancer risk for up to 5 years of treat-
ment duration; (2) there is limited evidence that estrogens combined with oral micronized progester-
one applied for more than 5 years are associated with an increased breast cancer risk; and (3)
counseling on combined MHT should cover breast cancer risk – regardless of the progestogen chosen.
Yet, women should also be counseled on other modifiable and non-modifiable breast cancer risk fac-
tors in order to balance the impact of combined MHT on the breast.
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The steroid hormone progesterone (P) plays a key role in
female reproduction1. For therapeutic reasons, micronized
progesterone (MP) can be used, for example, for endometrial
protection when estrogens are applied in menopausal
women with an intact uterus2. To discuss various topics on
MP, regular international expert meetings of three gyneco-
logical endocrinologists from the German-speaking countries,
Austria, Germany and Switzerland, have been held since 2015
aiming to provide scientifically proven statements on MP
treatment in peri- and postmenopausal women, based on a
systematic literature search and discussion of the results. The
impact of estrogens combined with MP on the mammary
gland, especially on breast density, biopsies (benign breast
tissue) and cancer risk is the second topic of this series3.
Material and methods
In May 2016, a systematic literature search was performed by
an independent agency (gwd consult) using the databases
Medline (Pubmed) and Embase. Only articles in English were
included. There was no time restriction applied. For each
topic (impact of MP on (1) breast biopsy, (2) breast histology
and (3) breast cancer risk), individual searches were per-
formed using multiple combinations of keywords, Mesh-
terms and text words related to the respective topic. For
the first topic, included keywords were ‘progesterone’,
‘breast’, ‘density’, ‘treatment’, ‘micronized’, ‘mammography’,
‘exogenous’, ‘hormone’, ‘proliferation’, ‘HRT’, ‘bio-identical’,
while ‘MPA’, ‘norethisterone’, ‘progestin’, ‘medroxypro-
gesterone’ and ‘receptor’ were excluded keywords. The
search yielded 60 relevant articles. For the second topic,
included keywords were ‘progesterone’, ‘histologic’,
‘treatment’, ‘breast’, ‘hormone’, ‘biopsy’, ‘parenchymal’, ‘bio-
identical’ and ‘histology’ and excluded keywords were
‘progestin’, ‘medroxyprogesterone’, ‘norethisterone’ and
‘receptor”. The search yielded 30 relevant articles. For the
third topic, included keywords were ‘progesterone’, ‘breast’,
‘cancer’, ‘risk’, ‘treatment’, ‘micronized’, ‘bio-identical’ while
excluded keywords included ‘receptor’ and ‘progestin”. The
search yielded 83 relevant articles. After exclusion of dupli-
cates, the final list of relevant articles comprised 141 out of
all relevant 173 articles. After May 2016, five additional
articles have been identified and included into the review4–8.
The final eligibility assessment and evaluation of the studies’
quality were performed by the expert group (PS, JN, LW).
Results
Of 143 hits, 19 studies4–22 were selected for the systematic
review and expert panel’s discussion. The other publications
were excluded as they, for example, did not use MP but syn-
thetic progestins although stated otherwise in the title,
focused on infertility treatment or were not original articles,
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respectively. In the following, the term ‘progestogen’ was
used as an umbrella term for MP and synthetic progestins.
Breast density
Of 60 hits, only six articles were suitable for this review9–14
(Table 1). Of those, four were subgroup analyses of the
placebo-controlled, randomized-controlled trial (PC-RCT)
Postmenopausal Estrogen/Progestin Intervention (PEPI)
trial9–12, one was a post-hoc analysis of two PC-RCTs13 and
another one a head-to-head RCT14. Sample size ranged from
7714 to 57110 postmenopausal women. Treatment duration
ranged from 2 months14 to 3 years9. Within the PEPI trial, four
menopausal hormone therapy (MHT) regimens were compared
to placebo9–12. MHT regimens comprised oral conjugated
equine estrogens (CEE) at 0.625mg/day (o-CEE), o-CEE at
0.625mg/day combined with oral medroxyprogesterone acet-
ate (o-MPA) at 10mg/day for 12 days per month (o-CEEþ o-
seqMPA), o-CEE at 0.625mg/day combined with o-MPA at
2.5mg/day (o-CEEþ o-contMPA), and o-CEE at 0.625mg/day
combined with oral MP (o-MP) at 200mg/day for 12 days per
month (o-CEEþo-contMP). The post-hoc analysis combined
two Danish RCTs13 comparing placebo to either an oral MHT or
nasal–oral MHT regimen. The oral MHT regimen contained oral
17b-estradiol (o-E2) at 1mg/day combined with trimegestone
at 0.125mg/day (o-E2þ o-contTrimegestone), whereas the
nasal–oral MHT contained either nasal E2 at 150 or 300 mg/day,
respectively, combined with o-MP at 200mg/day for 14 days
per month in women with an intact uterus (n-E2 ± o-seqMP).
The head-to-head RCT14 used two different MHT regimes con-
taining either o-CEE at 0.625mg/day sequentially combined
with o-MPA at 5mg/day (o-CEEþo-seqMPA) or transdermal E2
(t-E2) gel at 1.5mg/day sequentially combined with o-MP at
200mg/day (t-E2þo-seqMP).
Mammographic density was assessed either categorically,
e.g. by Breast Imaging Reporting and Data System (BI-RADS)
grades9,13,14, or continuously, e.g. by computer-based mam-
mographic percent density10–13. After 1 year of MHT within
the PEPI trial, mammographic density was significantly
increased by all estrogen–progestogen regimens but not by
o-CEE or placebo9–11. There were no group differences
between combined MHT regimens9–11. All mammographic
density increases observed comprised only one category and
mostly appeared during the first year of MHT use9. Similarly,
mammographic density was significantly increased by oral
estrogens combined with trimegestone13 or MPA14. In con-
trast, mammographic density remained unchanged after
treatment with oral or nasal estrogens combined with
o-MP13,14. Furthermore, the associations between mammo-
graphic density and new-onset breast discomfort11, change
in serum progestogen levels or progesterone receptor geno-
type12 were analyzed. Women with new-onset breast discom-
fort had a 3.9% increase in mammographic density
regardless of MHT type11. Increases of serum progestogen in
the highest quartile were associated with 3.5% higher
mammographic density compared to increases in the lowest
quartile. However, there was no indication that genetic
variations in the progesterone receptor had an impact on
mammographic density or modified the impact of serum
progestogen levels on mammographic density12.
Breast biopsy
Of 30 hits, only three studies were prospective randomized
intervention trials14–17, of which one study used o-MP14,15
and two topical (applied directly on the breast) MP16,17,
respectively (Table 2). The latter two trials16,17 were both pla-
cebo-controlled with three active comparator arms: topical
MP 25mg/day, topical E2 gel 1.5mg/day, and the combin-
ation of both (E2þMP). Study duration was short and com-
prised 11–14 days prior to a scheduled surgery for the
removal of a breast lump. The cohorts included either 33 pre-
menopausal16 or 40 postmenopausal women17. The study
endpoints were similar, namely serum steroid levels (E2, P),
tissue steroid concentration (E2, P), mammary epithelial
mitotic index and cell proliferation marker (PCNA) expression.
While serum E2 levels were significantly higher in women
applying topical E2 compared to those applying MP or pla-
cebo, significant group differences for serum P levels were
only found in postmenopausal17 but not in premenopausal
topical MP users16. Tissue E2 concentration was significantly
higher in women applying topical E2 compared to those
applying placebo16,17 or MP17. Tissue P concentration was
significantly higher in women applying topical MP compared
to placebo16 or did not reveal any group differences17.
Mammary epithelial mitotic index was significantly increased
in those women applying topical E2 when compared to
those using topical MP16,17, E2þMP or placebo17. Similarly,
PCNA expression was highest in topical E2 users16,17 but still
significantly higher in women applying topical E2þMP com-
pared to women applying MP16 and placebo17. Both authors
came to the conclusion that topical MP for up to 14 days
reduced E2-induced mammary epithelial proliferation.
The impact of a 2-month systemic MHT containing MP on
the mammary gland in 77 healthy postmenopausal women
was investigated by one RCT yielding three publications14,15.
In this RCT, head-to-head comparisons were performed using
two different MHT regimes containing either o-CEE at
0.625mg/day sequentially combined with o-MPA at 5mg/day
(o-CEEþo-seqMPA) or t-E2 gel at 1.5mg/day sequentially
combined with o-MP at 200mg/day (t-E2þo-seqMP). Core
needle biopsy of the upper outer quadrant of the left breast
was performed at baseline and study end. Study endpoints
were breast cell proliferation (Ki-67/MIB-1) and apoptosis
(bcl-2) assessed by immunohistochemistry14,15, single gene
expression analysis assessed by reverse transcription poly-
merase chain reaction (rtPCR)14 and whole genome expres-
sion analysis by microarray14. Assessable breast samples at
both time points were available for 10%14 to 49%14,15 of sub-
jects. After 2months of treatment, breast cell proliferation
and Ki-67 gene expression were significantly increased by
o-CEEþ o-MPA but not by t-E2þo-MP14,15. In contrast, breast
cell apoptosis and bcl-2 gene expression were either
decreased by t-E2þo-MP or did not reveal group differen-
ces14,15. Induction of progesterone receptor B expression was
slightly but not significantly lower after t-E2þ o-MP than
o-CEEþ o-MPA treatment14. Microarray analysis revealed an















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































altered gene expression profile (fold change 1.5) for 2500
genes within the o-CEEþ o-MPA arm and 300 genes within
the t-E2þ o-MP arm14. A total of 225 genes were involved in
mammary tumor development of which 198 were attribut-
able to o-CEEþo-MPA and 34 to t-E2þo-MP. The different
aspects of the study came to the conclusion that, in compari-
son to ‘conventional’ MHT, transdermal E2 combined with
oral MP induced less proliferation and adverse expression of
important genes regulating proliferation, apoptosis and
tumor inclination in vivo.
Breast cancer risk
Breast cancer risk in respect to MHT containing MP was
assessed by two systematic reviews and meta-analysis4,7, one
retrospective cohort study18, two prospective cohort studies
(the Etude Epidemiologique de femmes e la Mutuelle
Generale de l’Education Nationale (E3N), and Menopause:
Risk of breast cancer, morbidity and prevalence
(MISSION))8,19–21,23,24, one case–control study (CECILE, a
population-based case-control study in Cote d’Or and Ille-et-
Vilaine)25 and two PC-RCT (Kronos Early Estrogen Prevention
Study (KEEPS)22, and Early versus Late Intervention Trial with
Estradiol (ELITE)5) (Table 3). The first meta-analysis7 included
two cohort studies8,24 and reported that breast cancer risk
was lower for estrogens combined with MP than with syn-
thetic progestins (relative risk (RR) 0.67; 95% confidence
interval (CI) 0.55–0.81). Mean MHT duration was 7.0 years24
and 8.3 years8, respectively. According to the second meta-
analysis covering 14 trials, breast cancer risk was increased
when estrogens were combined with MPA, norethisterone
(NET) or levonorgestrel (LNG) but not when combined with
dydrogesterone (DYD) or MP4, respectively. However, the dur-
ation of MHT use was not considered.
Except for the two US-American PC-RCTs, all other studies
were performed in France. The primary endpoints were
breast cancer risk8,18–21,23–25 or changes in carotid artery
intima-media thickness5,22. In the latter, breast cancer was
assessed as a serious adverse event5,22. The sample size
ranged from 6435 to 80 39123 postmenopausal women, and
mean follow-up from 4.022 to 11.221 years. At study entry,
women were in their fifties in all5,18–20,22–24 but two studies5,8
that also recruited women during late postmenopause. Only
CECILE did not report on participants’ age25. Information on
MHT use was obtained from medical records8,18, self-adminis-
tered questionnaires at baseline26 and then every 2
years19–21,23,24, in-person interviews25, and scheduled visits at
2-month5 or 12-month22 intervals. Mean duration of MHT use
ranged from 2.8 years19 to 10 years18. Adherence to medi-
cation was high in KEEPS (>94%)22 and ELITE (98%)5 but not
reported in the other studies included.
Both PC-RCTs, KEEPS22 and ELITE5 used a sequentially
combined MHT. In KEEPS, o-CEE at 0.45mg/day or t-E2 patch
at 50 mg/day was combined with o-MP 200mg/day on days
1–12 of each month (o-CEEþo-seqMP, t-E2þo-seqMP)22. In
ELITE, o-E2 at 1mg/day was combined with vaginal MP at
45mg/day (4% gel) on 10 days during each 30-day cycle
(o-E2þ vag-seqMP)5. The observational cohort and case–control





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MP8,18–21,23–25, DYD18,20,21,23,24 and synthetic progestins (pro-
gesterone- and testosterone derivatives)8,18,19,21,23–25 but not
between estrogen types, MHT dosages and MHT regimen
(sequentially or continuously combined MHT). The definition
of current and past MHT use differed between studies. For
some, current MHT use corresponded to systemic estrogen
therapy for 1 year18–20,24. For others, current systemic MHT
also comprised women that had stopped MHT use 1 year25
or even 5 years8 before the reference date, which in con-
trast was defined as past use in another study21. One study
grouped current and past MHT use together23.
The first study to report on the impact of different proges-
togen types within combined MHT on breast cancer risk did
not find a significant difference between combined MHT use
and non-use (adjusted RR 1.10; 95% CI 0.73–1.66)18. This find-
ing was not altered when differentiating between time since
last MHT use (<5 years vs. 5 years) and duration of MHT
use (<5 years vs.  5 years). Unfortunately, subgroup analysis
for progestogen types was not performed. However, the
majority of combined MHT contained MP (58%) or DYD
(10%) and only <3% MPA. The MISSION trial did not find a
significant difference for breast cancer risk when comparing
MHT users with non-users (non-adjusted RR 0.91; 95% CI
0.45–1.86)8. Similarly, breast cancer risk in MHT users did not
differ between MHT types and duration of use (5 years vs.
>5 years). In contrast, when compared to MHT non-use, the
first E3N report from 2005 found a significant increased
breast cancer risk for any combined MHT use (multivariate
adjusted RR 1.3; 95% CI 1.1–1.5)19. Breast cancer risk was not
altered by duration of MHT use (<2 years vs. 2–4 years vs.
4 years; p for trend¼ 0.7). However, when differentiating for
progestogen type, estrogens combined with oral MP were
not associated with an increased breast cancer risk (multivari-
ate adjusted RR 0.9; 95% CI 0.7–1.2), while estrogens com-
bined with synthetic progestins were (multivariate adjusted
RR 1.4; 95% CI 1.2–1.7). Duration of MHT use (<2 years vs.
2–4 years vs. 4 years) only had a slight impact when oral
estrogens were combined with synthetic progestins (p for
trend¼ 0.07) but not when combined with MP (p for
trend¼ 0.9). Similarly, the second E3N report published in
2008 did not find an increased breast cancer risk for com-
bined MHT containing either MP or DYD regardless of MHT
duration (<2 years vs. 2–<4 years vs. 4–<6 years vs.
6 years), although a significant time trend was observed in
women using estrogens combined with MP (p for
trend¼ 0.04)24. In addition, combined MHT containing MP
was not found to be associated with any breast cancer sub-
type23. These findings were supported by CECILE25. However,
the numbers of cases and controls were very small in sub-
groups and the authors did not differentiate between inva-
sive and in situ breast cancer. In contrast, the third E3N
report from 2014 found a significant increased breast cancer
risk for mean 6.1 years of use of combined MHT containing
MP or DYD (multivariate adjusted RR 1.22; 95% CI 1.11–1.35).
When differentiating between short-term (5 years) and
long-term use (>5 years), a significant increased breast cancer
risk was only found for long-term use (multivariate adjusted
RR 1.31; 95% CI 1.15–1.48). In comparison, use of combined
MHT containing synthetic progestogens for more than 5 years
was associated with an increased breast cancer risk (multi-
variate adjusted RR 1.98; 95% CI 1.73–2.26). Importantly, after
stopping MHT containing MP or DYD after >5 years of use,
breast cancer risk dissolved immediately (3months to 5 years
since last use: multivariate adjusted RR 1.15; 95% CI
0.93–1.42). In contrast, breast cancer risk was still elevated
even 5–10 years after stopping MHT containing synthetic pro-
gestins when use was at least 5 years (multivariate adjusted
RR 1.34; 95% CI 1.04–1.73). The time gap between meno-
pause and MHT initiation did not have an impact on breast
cancer risk in women using estrogens combined with
MP20,21. In the two PC-RCTs, breast cancer was newly diag-
nosed in eight women in KEEPS22 (n¼ 3 o-CEE, n¼ 3 t-E2,
n¼ 2 placebo), and in 18 women in ELITE5 (n¼ 10 o-E2, n¼ 8
placebo), respectively. The difference between MHT and pla-
cebo groups was not significant in both studies.
Discussion
Current international guidelines on MHT recommend to com-
bine a progestogen when using estrogen therapy in peri-
and postmenopausal women with an intact uterus for endo-
metrial protection2,27–29. However, long-term combined estro-
gen–progestogen therapy has been shown to be associated
with an increased breast cancer risk. During the last years,
the debate about (compounded) bioidentical hormones has
increased tremendously30–32. Specifically, the question has
been raised whether bioidentical hormone therapy including
MP has a different or even beneficial impact on the mam-
mary gland. Internationally, systemic MP is available at differ-
ent dosages and routes of application. Also, indication and
approval by regulatory authorities may differ from country to
country. In Europe, systemic MP is available as a capsule
(100mg, 200mg) for vaginal or oral application or as a vagi-
nal gel (8% corresponding to 90mg).
Our systematic review on the impact of estrogens com-
bined with MP on the postmenopausal mammary gland
showed that (1) mammographic density may either increase
or remain unchanged, (2) proliferation induction was less
pronounced compared to ‘conventional’ MHT, and (3) breast
cancer risk was not affected for up to 5 years of treatment.
However, (4) estrogens combined with MP or dydrogesterone
were associated with a slight but significant increase in
breast cancer risk after an average of 6 years of treatment
duration.
Breast density is a mammographic finding based on differ-
ing proportions of fat, connective and epithelial tissue.
Mammographic density can be assessed either by the BI-
RADS classification (almost entirely fatty, scattered areas of
fibroglandular density, heterogeneously dense, extremely
dense)33 or by more objective, but not widely implemented
computer-based breast density assessments34–36.
Mammographically dense breast tissue both decreases the
sensitivity of mammograms and increases breast cancer risk37
but not breast cancer mortality38. There are multiple factors
contributing to mammographic density such as age, genetics,
body habitus, parity, and MHT use. Our systematic review
revealed contradicting results for MHT containing MP, with
120 P. STUTE ET AL.
two studies showing no change13,14 and three substudies
showing a significant increase in mammographic density9–11.
The latter are in line with another longitudinal study showing
that the age-related change from dense to fatty breast tissue
was slowed down more in women taking combined MHT
than in those taking estrogen alone39. The differing results
may also be due to the method itself and differences
between the US-American4–6 and European13,14 cohorts. US-
American women were in their late fifties, overweight and
had mostly used MHT before4–6, while European women
were younger at least in one substudy13 and had a normal
body mass index8,9. Baseline mammographic density was
reported by all but one study14. Most women (approximately
60%) fell into the BI-RADS categories 1 and 29–11,13. However,
mammographic density interpretation is subjective to some
degree as moderate interobserver and intraobserver variabil-
ities, especially between the BI-RADS categories of heteroge-
neously dense and scattered areas of fibroglandular density,
have been reported40–42. Accordingly, a striking but non-sig-
nificant interobserver variability was reported by one study9.
Due to heterogeneous study designs, reports on the
impact of estrogens combined with MP on breast tissue were
not comparable. Outcome markers differed, ranging from tis-
sue sex steroid concentrations, immunohistochemistry, rtPCR
to microarray gene expression analysis. Study duration was
short and 2months at maximum. Furthermore, two studies
used topical MP16,17 which is not thought to have a systemic
impact43. The observed differences in tissue E2 and P con-
centrations may be due to pharmacological interference and
different reproductive stages. Thus, there is only some weak
evidence from breast biopsies in healthy women showing
that estrogens combined with oral MP are more ‘breast
friendly’ than estrogens combined with oral MPA, a finding
supported by studies in non-human primates44,45.
In respect to breast cancer risk, all studies confirmed that
estrogens combined with MP did not increase breast cancer
risk when treatment duration was 5 years or less. The only
two studies assessing breast cancer risk in women using MHT
containing MP for more than 5 years are the prospective
cohort studies E3N and MISSION. Yet, compliance, dosage
and route of application of MP were not exactly known. In
addition, the E3N report from 2014 did not differentiate
between MP and dydrogesterone. Another limitation of E3N
was the high rates of MHT changes over time: of those who
ever used estrogens combined with MP or dydrogesterone,
57% also used estrogens combined with synthetic progesto-
gens21. The majority of studies used oral MP, which is the
approved way of application for MHT. Thus, breast safety
data on vaginal MP is scarce5 or completely lacking for trans-
dermal MP. Despite the limited evidence, women should be
counseled that, if using combined MHT for more than 5 years,
the risk of being diagnosed with breast cancer increases –
regardless of the progestogen type chosen. However, in
order to balance the impact of non-modifiable (e.g. genetics,
breast density, parity) and modifiable breast cancer risk fac-
tors (e.g. alcohol, smoking, overweight/obesity, physical
inactivity, MHT), women should also be counseled that the
possible increased breast cancer risk with combined MHT is
small (<1 per 1000 women per year of use) and lower than
the increased risks associated with common lifestyle factors
such as reduced physical activity, obesity and alcohol
consumption46.
Conclusion
Postmenopausal women with an intact uterus using estrogen
therapy should receive a progestogen for endometrial pro-
tection. Based on a systematic literature review on the
impact of micronized progesterone on the mammary gland,
an international expert panel’s recommendations on MHT
containing micronized progesterone are as follows: (1) estro-
gens combined with oral (approved) or vaginal (off-label use)
micronized progesterone do not increase breast cancer risk
for up to 5 years of treatment duration; (2) there is limited
evidence that estrogens combined with oral micronized pro-
gesterone applied for more than 5 years are associated with
an increased breast cancer risk; and (3) counseling on com-
bined MHT should cover breast cancer risk – regardless of
the progestogen chosen. Yet, women should also be coun-
seled on other modifiable and non-modifiable breast cancer
risk factors in order to balance the impact of combined MHT
on the breast.
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